Cameron Reynolds CEO, VolitionRx Jake Micallef, Ph.D., CSO, VolitionRx VolitionRx (Belgium) is tackling cancer diagnostics 160 base pairs (BP) at a time. The company’s nucleosome- based detection technology is able to detect, measure, and analyze cancer-causing mutations using a drop of blood on widely available enzyme-linked immunosorbent assay (ELISA) platforms. The company will commercially roll out the first of its NuQ tests—for colorectal cancer (CRC) detection— in Europe later this year, while it completes further validation on NuQ tests for prostate, lung, and pancreatic cancer. The company believes its low-cost, noninvasive test is a solution for the compliance problem associated with other CRC screening methods and could establish itself as an accurate screening test in other cancer areas. DTET recently spoke to VolitionRx’s CEO Cameron Reynolds and Chief Scientific Officer Jake Micallef, Ph.D., about the company’s technology and upcoming commercialization plans. Why is your technology based on nucleosomes? Micallef: Actually, nucleosomes are the biomarker that everybody is using right now, although they just are not calling it that. Most of the companies involved in new cancer detection technologies in blood look at DNA sequences. As the name suggests, circulating tumor DNA (ctDNA) technologies analyze tumor DNA that is circulating in […]